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RHEUMATOID arthritis  (RA)  is  characterized  by  an
abnormal  cellular  and  cytokine  infiltration  of
inflamed joints. This study addresses a previously un-
recognized interaction  between  neutrophilic-myelo-
peroxidase  (MPO)  and  macrophages  (Mø)  which
could explain the perpetuation of inflammation asso-
ciated with RA. A monoarticular arthritis was induced
in female Lewis rats by injection of streptococcal cell
wall extracts (PG-APS). After swelling and erythema
subsided,  joints  were  re-injected  with  one  of  the
following: porcine MPO or partially inactivated MPO
(iMPO). Injection with either MPO or iMPO induced a
‘flare’ of experimental RA. Blocking the Mø-mannose
receptor  by  mannans,  ablated  exacerbation  of  dis-
ease.  These  results  indicate  that  MPO  or  iMPO  can
play  a  pivotal  role  in  the  perpetuation  but  not
initiation of this RA model.
Key words: Autoimmunity,  Peroxidases, TNF-a ,  Rheuma-
toid arthritis, Reactive oxygen intermediates
Introduction
Rheumatoid arthritis (RA) is an inflammatory autoim-
mune  disease  of  unknown  etiology.
1–3 It  is  known
that  this  inflammatory  disease  affects  the  synovial
membranes of various joints and that there is de novo
vascularization beneath the synovial lining along with
an  orchestrated  infiltration  of  the  joint  by T  and  B
lymphocytes  as  well  as  macrophages  (Mø).  Several
investigators  have  reported  the  association  of  Mø
with the pathology of RA.
4–7 Moreover, it has been
reported that 80–100% of those cells which line the
synovium are Mø.
8 In addition to the Mø, neutrophils
are  abundant  in  the  synovial  fluid  and  it  has  been
reported that both cell types are found in a state of
heightened activation.
2,3,8 It has recently been repor-
ted that Mø directly influence a neutrophil-dependent
inflammatory  response  and  that  the  neutrophil,  in
turn, recruits and activates Mø.
9
Along with the presence of the above cell types, it
is  documented  that  there  are  abnormal  levels  of
numerous  cytokines  in  an  RA  joint.
1,8 Among  the
cytokines present are the following: tumor necrosis
factor a (TNFa ), IL-1, IL-6, IL-8 as well as others.
7,10,11
However, of the cytokines reported to be present in
the RA joint, TNFa is believed  to be  pivotal  to the
disease process.
1,7 Since TNFa initiates a cascade of
pro-inflammatory cytokines,
7,10,11 the central role of
this cytokine in the disease process is not surprising.
Several investigators have reported that the primary
source of TNFa in an RA joint is the Mø;
12,13 however,
the factor(s) which are responsible for stimulation of
these cells to secrete TNFa have not be identified.
Since  it  has  been  reported  that  neutrophils  are
abundant in the synovial fluid of the RA joint,
2,3,5 one
would  also  expect  myeloperoxidase  (MPO)  to  be
present. In fact, other investigators have documented
the presence of enzymatically active MPO as well as
16–29 m g/ml  of  enzymatically  inactive  MPO  in  RA
joints.
14,15 These studies indicate that both forms of
the enzyme may be associated with RA.
In other studies completed in this laboratory, data
indicated that recombinant human MPO and enzymat-
ically inactive MPO enhanced the following resident
murine  Mø  functions:  (1)  respiratory  burst,
16,17 (2)
secretion  of  TNFa ,  IL-6,  IL-8,  and  granulocyte-Mø
colony  stimulating  factor  (GM-CSF)  (unpublished
data), and (3) phagocytosis and intracellular killing of
Candida albicans and E. coli.
16–18 Myeloperoxidase
also induced elevated titers of TNFa and IFN a /b in
vivo.
19 Since it  has been  reported that  neutrophils,
MPO, enzymatically inactive MPO, and Mø are present
in  an  inflamed  RA  joint,  the  present  study  was
undertaken to determine if the interaction between
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could contribute to the ‘chronicity’ of inflammation
associated with experimental RA. A Lewis rat model
was employed to investigate the effect of neutrophilic
MPO on exacerbation of this disease. The disease was
induced  using  a  single  intra-articular  injection  of
streptococcus A  cell  wall  fragments  (PG-APS). After
development of experimental RA, either porcine MPO
or partially inactivated porcine MPO was injected into
the same joint to determine what effect this enzyme
had on exacerbation of the disease. For convenience,
in the remainder of this manuscript, RA will be used
to designate mono-articular  experimental  RA unless
otherwise stated.
Materials and Methods
Myeloperoxidase
The use of rat MPO would have been preferred, but it
was not available. Highly purified porcine MPO was
generously provided by Dr R.C. Allen. The mannose
content of this preparation was 4.6% and it contained
1539  units/ml  of  activity  using  o -dianisidine  as  a
substrate. Cathepsin  G, a  serine protease, has been
reported  to  be  present  in  neutrophils.  Trypsin,
another serine protease, was used to generate inactive
MPO as follows: Myeloperoxidase was partially inacti-
vated by exposure to trypsin-Sepharose 4B gel slurry
(Worthington  Biochemicals,  Freehold,  NJ).  Prior  to
mixing the MPO and the gel slurry together, a 1:12
dilution of MPO was heated to 70°C for 10 min. After
the solution cooled to below 37°C, the diluted MPO
was mixed with the slurry at a 4:1 ratio of MPO to
trypsin  for  the  digestion.  Digestion  was  allowed  to
proceed  for  6 h  at  37°C. After  this  incubation,  the
supernatant  was  collected,  aliquoted,  and  stored at
–20°C until used. This preparation of MPO exhibited
123 units/ml of activity as measured by o -dianisidine.
For  the  remainder  of  this  manuscript,  the  partially
inactivated MPO will be referred to as iMPO.
Animals
Age  matched  female  Lewis  rats  weighing  approx-
imately  180 g  were  obtained  from  Harlan  Sprague
Dawley, Indianapolis, IN. Animals were cared for and
housed in a facility according to the guidelines of the
Animal Welfare Act.
Reagents
The Limulus amebocyte lysate (LAL) assay was used
to test all reagents for LPS contamination. The stock
MPO preparation  contained £ 0.08 ng/ml of LPS. The
amount of LPS in the inactivated MPO was the same
after exposure to trypsin beads. Materials for the LAL
assay  were  purchased from Associates of Cape Cod
(Woodshole,  MA).  Immunocytochemistry  reagents
which  were  purchased  from  Sigma  (St  Louis,  MO)
included: diethylpyrocarbonate, Mayer’s hematoxylin
solution,  bovine  serum  albumin  (fraction V)  (BSA),
and  diaminobenzidine.  Other  reagents  which  were
purchased  from  Fisher  Scientific  (Pittsburgh,  PA)
were: Superfrost-plus microscope slides, xylene, per-
mount, and TRIS base. Saccharomyces cervisiae was
the  source  of mannans which  was  purchased  from
Fluka Biochemika, Switzerland. Mannosylated bovine
serum  albumin  (M-BSA)  was  purchased  from  E.Y.
Laboratories (San Mateo, CA).
Cells
Resident rat peritoneal Mø were collected by perito-
neal  lavage  similar  to  the  procedure  previously
described  by  the  present  investigators.
17,18 Briefly,
after  the  cell  suspension  was  removed  from  the
abdominal  cavity  and  centrifuged  at  1000 rpm  for
10 min  at  4°C,  red  blood  cells  were  lysed  using
hypotonic  phosphate  buffered  saline  (PBS).  After
centrifugation, the supernatants were decanted and
the peritoneal cells diluted to 1.2 3 10
6 cells/ml and
resuspended in Dulbecco’s modified Eagle’s medium
(Gibco, Long Island, NY) containing HEPES (Sigma),
sodium bicarbonate, and gentamicin sulfate (Sigma).
Subsequent to a 2-hour incubation, monolayers were
washed vigorously with media to remove non-adher-
ent  cells.  Using  staining  procedures,  it  was  deter-
mined that the adherent cell cultures were ‡ 99% pure
Mø. Subsequently, Mø monolayers were exposed to
different concentrations of either MPO or iMPO. After
various incubation periods, supernantants were col-
lected and stored at –70°C until used. ELISA kits for
TNFa were  purchased  from  Genzyme  (Cambridge,
MA),  and  the  manufacturer’s  instructions  were
followed.
Arthritis Model
Female Lewis rats were used for the induction  of a
mono-articular arthritis. The right ankle joint (which
was the negative control) was injected with 10 m l of
normal  saline. The  left  ankle  joint  (which  was  the
experimental joint) was initially injected with 10 m l of
a sterile, aqueous suspension of PG-APS (a generous
gift from Dr S. Lichtman, University of North Carolina,
Chapel Hill, NC) containing a dose equivalent to 2 m g
of  rhamnose.
20,21 A  27  gauge  0.5  inch  needle  was
inserted though the Achilles tendon above the calca-
neous into the vicinity of the tibiotalar joint. For all
injections,  the  animals  were  sedated  by  ether
inhalation.
After IA injection of PG-APS, the joints increased in
diameter  by  approximately  1–2 mm  (5.8  to
7.0–8.0mm) within 24–48 h. Over a period of 7–21
days,  these  joints  decreased  in  swelling  to  approx-
imately 6.5 mm. Since no further decrease in diameter
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considered  to be ‘baseline’  level of swelling. There-
fore, when a PG-APS treated joint measured 6.5 mm,
both  ankle  joints  were  re-injected:  the  right  joint
received  10 m l  of  normal  saline,  and  the  left  joint
received 10 m l of various treatment solutions. Those
joints  which  increased  in  size  by  a  minimum  of
0.5 mm  24–48  hours  after  re-injection  were  con-
sidered positive for inflammation. On a daily basis, the
peri-articular  swelling  of  both  treated  and  control
ankle joints was monitored. The peri-articular swelling
was measured with a caliper starting on day zero, and
continued daily until the study was completed.
Histology
Post-mortem,  both  hind  legs  were  harvested  and
processed  as  previously  described  by  other  inves-
tigators.
20 –22 The severity of the arthritis was scored
on  a  scale  of  0–3  for  synovial  hyperplasia  and
inflammation,  tissue  erosion,  and  the  presence  of
neutrophils. All histological sections were read blin-
ded by Suzanne Graham, MD, Department of Pathol-
ogy  at  Texas  Tech  University  Health  Sciences
Center.
Immunocytochemistry
Post-mortem, treated (left) and control (right) ankle
joints  were  harvested  and  prepared  for  immunocy-
tochemistry.
22 Sections  were  placed  on  Superfrost/
Plus slides and deparaffinized. Subsequently, sections
were  treated with  3%  H2O2 to  destroy endogenous
peroxidase  activity.  After  H2O2 treatment,  sections
were incubated with a rabbit polyclonal antibody to
TNFa (Calbiochem,  La  Jolla,  CA)  overnight  at  4°C.
Normal rabbit IgG (Sigma) was used as a control. After
several washes with PBS buffer, sections were incu-
bated with biotinylated anti-rabbit  IgG for 30 min at
room  temperature.  Incubation  for  an  additional
30 min  was  performed  with  an  avidin:biotinylated
enzyme  complex (VECTASTAIN ABC  system, Vector
Laboratories,  Burlingame,  CA).  Diaminobenzidine
was used as a substrate. Subsequently, sections were
counterstained  with  hematoxylin  and  examined
microscopically.
Statistical analysis
A  two-tailed  Student’s  t-test  was  used  to  determine
significance between groups. Most data are presented
as the mean ±S.E.M.
Results
Since it is known that TNFa is pivotal to human RA
and initiates a cascade of pro-inflammatory cytokines,
initial experiments were done to determine if either
MPO or iMPO could induce TNFa secretion by Mø in
vitro. Exposure of resident rat peritoneal Mø to either
MPO or iMPO induced markedly higher titers of TNFa
than that obtained from the control cultures. It can be
noted  from  Fig.  1  that  iMPO  induced  a  dose-
dependent  increase  in  TNFa secretion  with  peak
titers  being  obtained  at  6 h.  If,  however,  MPO  was
employed,  an  increase  in TNFa was  observed  with
20 m g/ml  but  not  with  0.2 m g/ml.  At  the  highest
concentration  (20 m g), MPO  induced approximately
50%  less  cytokine  than  iMPO  (data  not  shown).  It
should  be noted that  the level of endotoxin  in  the
most  concentrated  preparation  of  either  MPO  or
iMPO  employed  in  these  studies  contained
£ 8 3 10
–3 ng/ml.  This  level  of  endotoxin  did  not
induce TNFa in vitro as determined by ELISA (data
not shown).
The next set of experiments was done in vivo to
determine if either form of the enzyme alone could
initiate arthritis. After  an  initial  injection  of  saline,
animals  were  injected  weekly  for  3  consecutive
weeks with various concentrations of either MPO or
iMPO. In  addition, a non-specific protein, mannosy-
lated BSA, was also tested. None of these substances
initiated the clinical symptoms of arthritis as noted by
swelling and erythema. Also, since LPS contamination
is ubiquitous, and this substance activates Mø, levels
of  endotoxin  (10 ng/joint)  that  were  approximately
1 3 10
5 times higher than the concentration found in
any  of  the  solutions  employed  in  this  study  were
injected  IA.  The  same  results  as  that  for  other
initiators  were  obtained,  i.e.  there were no  clinical
symptoms of arthritis as determined by swelling and
erythema (data not shown).
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FIG. 1. Induction of tumor necrosis factor-alpha (TNFa ) by
enzymatically inactive myeloperoxidase (iMPO). Resident rat
peritoneal  macrophage  (Mø)  were  cultured  in  a  96  well
Costar  plate.  After  a  2-hour  incubation,  the  cells  were
washed, and either treatments or media alone were added.
The  supernatants  from  treated  and  control  wells  were
collected  and  stored  at  –70°C  until  used  for  an  ELISA.
Manufacturer’s instructions were followed.Since  it  had  been  established  that  LPS  at  the
above  concentration  could  not  initiate arthritis,  a
number of animals were injected IA with LPS after
PG-APS  treatment.  When  10 ng/joint  of  LPS  were
injected  IA,  there  were  no  clinical  symptoms
observed.  It  should  be  noted  that  this  cycle  was
repeated twice with identical results. When 15 m g of
BSA  (a  substance  to  which  Lewis  rats  should  not
respond)
23 was repeatedly injected IA after PG-APS,
once  again,  no  clinical  symptoms  were  observed
(data  not  shown).
Various  concentrations  of  either  MPO  or  iMPO
were employed after arthritis was initiated with PG-
APS.  Concentrations  employed  varied  between  0.2
and  20 m g  in  10 m l.  If  0.2 m g  was  injected  IA,
approximately 50% of the animals exhibited RA after
each  injection  series.  If  20 m g  were  employed,  all
animals developed RA with 66% displaying ‘chronic’
arthritis. That is, the joints did not return to ‘baseline’
swelling within a 2 month period after the initial MPO
injection  (data  not  shown).  If  2 m g  of  MPO  were
injected  after  PG-APS,  the  initial  response  was  not
positive, whereas, a second injection exacerbated a
flare of the disease (Fig. 2a). However, when 2 m g of
iMPO were injected after PG-APS, all animals exhib-
ited swelling and erythema in the injected joints. This
pattern was repeated after a  second  IA  injection  of
iMPO  was  administered  (Fig.  2b).  Because  of  the
above responses, 2 m g/10 m l were employed for the
remainder of the study.
As  stated  previously,  in  vitro experiments  had
demonstrated that either MPO or iMPO could induce
TNFa . Therefore,  experiments  were  done  to  deter-
mine  if  TNFa was  pivotal  in  the  exacerbation  of
arthritis observed after IA injections of either MPO or
iMPO. After  joints  were  injected  with  PG-APS  and
swelling as well as erythema  had  returned to ‘base-
line’, IA  injections of MPO alone, iMPO alone, anti-
TNFa alone, MPO and anti-TNFa , or iMPO and anti-
TNFa were administered. Figure 3 depicts the results
of an  MPO+anti-TNFa experiment. The presence of
anti-TNF-a completely ablated the effect of MPO with
respect to exacerbation of a flare of RA. Similar results
were obtained with iMPO (data not shown).
Myeloperoxidase is known to be taken up by Mø
via  the  Mø  mannose  receptor  (MMR).
24 It  was
hypothesized that  blocking  the MMR should inhibit
clinical  symptoms.  Mannans  are  frequently  used  to
block the MMR;
25 therefore, after joints were injected
with PG-APS and  had returned to ‘baseline’ level of
swelling, IA injections were administered with one of
the  following:  mannans  alone,  MPO  alone,  iMPO
alone,  MPO  and  mannans,  or  iMPO  and  mannans.
Mannans  alone  did  not  elicit  any  joint  swelling  or
erythema. When  MPO  was  injected in  combination
with  mannans,  the  same  results  were  obtained  as
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FIG.  2.  (a)  Exacerbation  of  peri-articular  swelling  after  re-injection  of  pre-treated  joints  with  enzymatically  active
myeloperoxidase (MPO). On day 0, animals were injected with 10m l PG-APS (2m g of rhamnose/joint) in the left ankle joint and
10m l normal saline in the right ankle joint. After the treated joint returned to ‘baseline’ level of swelling/erythema, the
exacerbation regimen was started. On days 6 and 12 (as depicted by the arrows), animals were re-injected with 10m l MPO (left
ankle joint) and  10m l normal  saline (right ankle joint). These values represent the results  of at least 3–5 animals. The
experiment was repeated at least once. ***P£ 0.001. (b) Periarticular swelling after re-injection of PG-APS pre-treated joints
with enzymatically inactive myeloperoxidase (iMPO). On day 0, animals were injected with 10m l PG-APS (2m g of rhamnose/
joint) in the left ankle joint and 10m l normal saline in the right ankle joint. After the treated joint returned to ‘baseline’, the
exacerbation regimen was started. On days 11 and 18 (as depicted by the arrows), animals were re-injected with 10m l iMPO
(2m g/joint): left ankle joint and 10m l normal saline (right ankle joint). Graphed values represent the results of 3–5 animals. The
experiment was repeated at least once. The concentrations reflected in the graph are those present in the joint. ***P£ 0.001.those for mannans alone (Fig. 4), i.e. no effect. Similar
results were obtained with iMPO (data not shown).
Histological examinations of joints which received
the various treatment modalities were done. Table 1
describes the observations obtained. Minimal  to  no
pathology  was  noted  in  joints  injected  with  saline.
Minimal  pathology  did  persist  at  1  month  after  a
single injection of PG-APS. If MPO was employed as
an initiator and injected once a week for 3 weeks at
the  high  dose  of  20 m g  in  10 m l,  the  pathology
Perpetuation of inflammation associated with arthritis
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FIG. 3. The inhibition of peri-articular swelling after simulta-
neously  injecting  enzymatically  active  myeloperoxidase
(MPO) and anti-tumor necrosis factor-alpha (anti-TNFa ). On
day  0,  animals  were  injected  with  10m l  PG-APS  (2m g  of
rhamnose/joint) in the left ankle joint and 10m l normal saline
in the right ankle joint. After the treated ankle joint returned
to ‘baseline’ levels of swelling and erythema, the re-injecting
regimen was started. On days 9, 15, and 19 (as depicted by
the arrows), animals were re-injected simultaneously in the
left ankle joint with one of the following: 10m l MPO alone
(2m g/joint), or a combination of 5m l MPO (2m g/joint) and 5m l
anti-TNFa . The right ankle joint was re-injected with 10m l
normal  saline.  These  values  represent  the  results  of  3–5
animals. The experiment was repeated  at least once. The
concentrations reflected in the graph are those injected into
the joint. ***P£ 0.001.
FIG. 4. The inhibition of peri-articular swelling after injecting
simultaneously  enzymatically  active  myeloperoxidase
(MPO) and mannans. On day 0, animals were injected with
10m l of PG-APS (2m g rhamnose/joint) into the left ankle joint
and 10m l normal saline into the right ankle joint. After the
treated  ankle  joint  returned  to  ‘baseline’,  the  re-injecting
regimen was started. On days 9, 15, and 19 (as depicted by
the arrows), animals were re-injected simultaneously in the
left ankle joint with one of the following: 10m l MPO alone
(2m g/joint), or a combination of 5m l MPO (2m g/joint) and 5m l
mannans. The right ankle joint was re-injected with 10m l of
normal saline. Graphed values represent the results of 3–5
animals. The experiment was repeated  at least once. The
concentrations reflected in the graph are those injected into
the joint. ***P£ 0.001.
Table 1 
Treatment Synovial
hyperplasia
Synovial
inflammation
Percentage
PMN
Exudate Bone erosion
Salinea 0 0 0 0 0
MPO (20m g)a + + 0 0 0
PG-APSb + + + 0 0
MPO (20m g)c +++ +++ +++ +++ +++
iMPO (2m g)c ++ +++ ++ +++ ++
MPO (2m g)c +++ +++ + + +++
MPO (2m g) ++ ++ + + ++
+ Mannans (150m g/ml)c
BSAc + + + + +
a Values represent the pathology observed after 3 weekly IA injections without an initial injection of PG-APS.
b Pathology at 3 weeks after a single injection of PG-APS and 3 weekly injections of saline.
c Values represent the pathology observed after a single 10m l injection of PG-APS followed by 3 IA injections of the stated treatment. Each
injection was administered after the joint had returned to baseline level of swelling. Amounts in parenthesis represent the concentration
injected in the joint. Data represent the mean of at least 4 different animals.
Key: Synovial hyperplasia; 0 = 0–2 layers, + = 3,4 layers, ++ = 5,6 layers, +++ = >6 layers. Synovial inflammation; 0 = <2 lymph, + = inflamm (not
crowded), ++ = inflamm (cell crowded), +++ = diffuse.  % PMN; 0 = <1%, + = <10% , ++ = 11–20%, +++ = >30%. Exudate; 0 = <1%, + = <10%, ++ = 11–20% ,
+++ = >30%. Bone erosion; 0 = none, + = only edge 1–2 joint surfaces or juxta bone, ++ = more extensive over surface or 2–5 foci, +++ = more
extensive or >5 foci.FIG. 5. Photomicrographs showing the detection of tumor necrosis factor-alpha (TNFa ) by immunocytochemical (ICC) methods
in the synovial tissue of experimental arthritic joints. Tissue was stained with VECTASTAIN ABC system and counterstained
with hematoxylin. (a) Photomicrograph of a ‘control’ ankle joint which was repeatedly injected with saline. For the purpose of
ruling out non-specific binding, sequential cuts of ‘control’ ankle joints were subjected to either anti-TNFa or normal rabbit IgG.
(b) Photomicrograph of a joint injected with a single injection of PG-APS and harvested at the same time as the joints pictured
in (a) and (c). (c) Distribution of TNFa positive cells in synovial tissue from rat ankle joints that were primed with PG-APS and
re-injected with enzymatically active myeloperoxidase (MPO).
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injection of PG-APS alone (after 3 weeks). That is: the
pathology observed after three weeks was agreeable
with what has been observed previously in the model.
However, if  RA  was  initiated with PG-APS  and  the
joint was subsequently injected with 20 m g of MPO,
there was extensive pathology (Table 1). If joints were
injected  once  with  PG-APS  and  then  with  2 m g  in
10 m l of either MPO or iMPO, the pathology was less
severe than that observed with the higher dose of the
enzyme.  No  marked  difference  in  pathology  was
noted between animals injected with 2 m g of either
MPO or iMPO. The presence of mannans diminished
the overall pathology observed (Table 1).
Since  either  MPO  or  iMPO  induced  clinical  and
pathological  changes  consistent  with  an  exacerba-
tion of arthritis, immunocytochemistry studies were
done to determine if  the Mø-like cells, which com-
prise the synovial lining of the inflamed joint, were a
source of TNFa . After initiation of RA with PG-APS and
IA  injection  of  either  MPO  or  iMPO,  animals  were
sacrificed and the joints prepared for staining. Figure
5a shows a section of a joint repeatedly injected with
saline.  Minimal  positive  staining  was  observed  in
widely spaced areas of the joint. Figure 5b shows a
section of a joint injected with a single injection of
PG-APS. Figure 5c shows a section of a joint injected
with PG-APS, allowed to return to baseline, and then
repeatedly injected with MPO. Note that those cells
lining the joint stained positive for TNFa . If animals
were  injected  with  PG-APS  followed  by  repeated
injections  of  iMPO,  the  staining  pattern  was  essen-
tially the same for TNFa as that obtained when MPO
was injected (data not shown). When normal rabbit
IgG  was  employed  instead  of  rabbit  anti-TNFa ,  no
non-specific staining was observed.
Discussion
Numerous  cell  types  including  neutrophils,  mono-
cytes/Mø,  and  T  cells  have  been  reported  to  be
present  in  the  synovial  fluid  of  human  RA
joints.
4,6,10,26 Also, numerous cytokines are found in
the synovial  fluid  of inflamed joints.
2,7,11 Of all the
cytokines present in  an  RA joint, it  is believed that
TNFa is  pivotal  to  the  disease  since  it  initiates  a
cascade  of  cytokines  associated  with  inflamma-
tion.
7,10,11 Tumor  necrosis  factor  a ,  induces  the
secretion of IL-1
7,10,11 as well as activates osteoclasts
in RA joints.
7,11 Moreover, IL-1 causes loss of proteo-
glycan  from  articular  cartilage  which  is  one  of  the
hallmarks of human RA.
4 The presence of TNFa and
IL-1 induces secretion of IL-8 and GM-CSF , as well as
an infiltration of both neutrophils and monocytes into
an  arthritic  joint.
4,27 The  cytokines,  IL-1, TNFa and
GM-CSF  cause  neutrophil  degranulation
4,28 which
would provide a continuous supply of both MPO and
iMPO to the joint.
Cells of Mø lineage have been reported to be the
major source of TNFa in a human RA joint
6,11,29 and
the intensity of additional Mø migration into the joint
correlates with clinical activity of human RA.
6 When
resident  rat  peritoneal  Mø  were  exposed  to  either
iMPO (Fig. 1) or MPO an increase in TNFa secretion
was  observed. Tumor  necrosis  factor  induction  by
iMPO  was  dose  dependent;  however,  this  was  not
true  when  MPO  was  employed.  This  could  be
explained  in  part  by  the  following:  MPO  induced
greater  amounts  of  reactive  oxygen  intermediates
(ROI) than MPO (unpublished data), and that ROI can
enhance  secretion  of  a  cytokine  as  well  as  oxidize
receptors
30 preventing cell signaling causing a reduc-
tion of secreted cytokine. Only at the highest concen-
tration of MPO, were the Mø stimulated sufficiently to
secrete TNF. Thus, minimal oxidation by iMPO would
result  in  greater  cell  signaling  and  consequently
higher titers of TNF (approximately 2-fold). These in
vitro studies suggest that  both MPO  and  iMPO  can
interact  with  Mø  in  the  microenvironment  of  an
arthritic joint.
It has been established that PMN’s within human
RA synovial fluid degranulate and secrete MPO into
the microenvironment.
5 Within 10 minutes of stimula-
tion of neutrophils, approximately 30% of their MPO
is secreted.
31 Of the 30% of the secreted enzyme, only
5%  retains  enzymatic  activity.
31,32 Results  of  other
studies  indicate  that  PMN’s  released  approximately
50% of their MPO at a site of inflammation. Also, with
respect  to  human  RA,  Davies  et  al.,  reported  the
presence  of  MPO  in  arthritic  joints.
5 Moreover,
Edwards  et  al.,  have  reported  that  there  are
16–29 m g/ml  of  enzymatically  inactive  MPO  in  the
synovial  fluid  of  a  human  arthritic  joint.
15 In  the
present study, the injection of 2 m g/joint (200 m g/ml)
of  the  enzyme  was  the  standard  concentration
employed. Since there is not a consensus among the
numerous studies completed to date with respect to
the amount of both MPO and iMPO in a human RA
joint, concentrations utilized in this study may well be
within ‘pathological range’.
From 0.2–20 m g of MPO injected into a joint did not
initiate RA within  24–48 h after injection, as deter-
mined by both  clinical and  pathological criteria.  In
this study, IA injections of either MPO or iMPO after
PG-APS  induced arthritis. The fact that  PG-APS,  but
not  MPO  or  iMPO,  could  initiate  arthritis  could  be
explained in part by the fact that PG-APS is a more
potent inducer of TNFa . Also, it is possible that MPO,
which is highly conserved in various species, is not
highly  immunogenic.  With  respect  to  prolonged
presence of this enzyme and the induction of RA, it
has been reported that highly cationic molecules have
been associated with retention in joints and arthrito-
genicity.
23 Retention  is  believed  to  be  due  to  the
interaction  of  the  cationic  molecule  with  the  neg-
atively charged cartilage.
23,34,35
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various treatments into a particular joint, there was
concern that the trauma alone of repeated injections
could induce inflammation associated with RA. There-
fore, BSA and/or saline was repeatedly injected into
PG-APS  treated  joints.  The  results  indicated  that
repeated  injections  were  not  sufficient  to  induce
marked clinical or pathological changes (Table 1).
Exacerbation of an arthritic flare can be induced by
a  number  of exogenous  substances such as LPS (at
higher  doses  than  those  employed  in  the  present
study) and microbial superantigens.
33 The purpose of
‘cycling’ the injections of either MPO or iMPO after an
initial injection of PG-APS was to simulate flares of the
disease which occurs in patients (Figs 2a and b). As
stated previously, the first injection of MPO, after PG-
APS, did not induce a positive flare whereas the first
injection of iMPO did induce an exacerbation of the
disease. A possible explanation  for this could be the
fact that MPO induces tissue damage through ROI.
30
Therefore, the first injection would result in predom-
inantly  tissue  damage  and  subsequent  immune  cell
recruitment.  However,  with  the  second  injection,
immune cells would now be present in the joint and
would induce higher titers of TNFa . With iMPO, an
initial  injection  would  favor  induction  of  proin-
flammatory  cytokines  and  rapid  recruitment  of
immune  cells  and  not  direct  tissue  damage  due  to
ROI.
Shepherd and Hoidal reported that MPO binds to
Mø via a specific receptor, the MMR.
24 Therefore, if
either MPO or iMPO was causing an exacerbation of
experimental arthritis and contributing to ‘chronicity’
of  the  disease,  then  inhibiting  the  binding  of  this
enzyme should ameliorate clinical symptoms. When
either  MPO  or  iMPO  were  injected  simultaneously
with mannans, there was no exacerbation of clinical
disease (Fig. 4) providing evidence for the importance
of  Mø-MMR-neutrophil  (i.e.  MPO  or  iMPO)  inter-
action. Pathology reports corroborated these results
(Table  1).  Since  PG-APS  is  a  polymer  of  acetylated
mannose, the same concept was applied to the model
itself.  If  MMR-PG-APS  interaction  was  sufficient  to
induce  RA,  then  via  competitive  binding,  mannans
should  diminish  or  prevent  the  initiation  of  the
disease. When  PG-APS  was  injected  simultaneously
with  mannans,  there  was  no  clinical  response
observed. Again this indicates a central role of the Mø-
MMR ligand interaction in the induction of arthritis
using this animal.
Synovial type A cells, which are of Mø lineage, are a
major  source  of  TNFa in  arthritic  joints.
8 Using
immunocytochemistry, TNFa was found only among
the mononuclear phagocytic cells of the lining of the
joint,  in  perivascular  areas,  and  in  the  pannus
22 of
joints injected with PG-APS followed by injection of
either MPO or iMPO. These results indicate that either
MPO or iMPO interacting with cells of the synovial
lining, which are of Mø-lineage, induce the produc-
tion  of  TNFa .  Also,  the  pattern  of  TNFa staining
parallels that observed in human RA.
Various  investigators  have  reported  that  T  cells
participate  in  the  pathological  events  of  RA.
36,37
However,  recognition  of  the  neutrophil  as  a  major
contributor to the pathology associated with RA has
only  recently  been  reported.
26 The  results  of  the
present study have described the importance of the
neutrophil-Mø interaction in exacerbation of inflam-
mation  associated  with  a  model  of  arthritis. These
results indicate that: (1) either MPO or iMPO induce
the secretion of TNFa by rat Mø in vitro or in vivo;
(2) neither form of the enzyme can initiate RA in the
rat model; (3) numerous exacerbations of arthritis are
initiated by repeatedly injecting either MPO or iMPO
into a joint pre-treated with PG-APS; (4) immunocy-
tochemistry studies indicated the presence of TNFa ;
(5) the presence of anti-TNFa inhibits either MPO or
iMPO induced exacerbation of PG-APS-induced arthri-
tis,  and  (6)  clinical  and  pathological  symptoms  of
arthritis can be ameliorated or ablated by blocking the
MMR which is one of the major receptors involved in
the uptake of this peroxidase by the Mø.
In conclusion, there appears to be a previously un-
recognized interaction of either MPO or iMPO with
Mø which could partially  explain the ‘chronicity’ of
inflammation observed in this model. A recent report
indicated  that  ‘the  products  of  the  MPO-H2O2-Cl
pathway can act as immunological modifiers provid-
ing  a  further  pathway  linking  acute  and  chronic
inflammation  and  innate  and  adaptive  immune  res-
ponses’.
9 Further  studies  are  needed  in  order  to
answer  the  question  as  to  whether  this  interaction
plays a role in ‘chronic’ inflammation associated with
human RA.
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